

Table of Contents

Executive Summary	8	Canada	79
Global overview	8	Overview	79
Competitive landscape	14	Systemic analgesics	83
Category review	18	Topical analgesics	87
NPD & innovation round-up	35	Mouth & dental analgesics	91
Beyond core pain categories	38	Outlook	92
CBD for pain	40	China	94
Outlook	41	Overview	94
Australia	43	Systemic analgesics	98
Overview	43	Topical analgesics	105
Systemic analgesics	47	Mouth & dental analgesics	110
Topical analgesics	53	Outlook	112
Mouth & dental analgesics	57	France	114
Outlook	58	Overview	114
Brazil	60	Systemic analgesics	118
Overview	60	Topical analgesics	125
Systemic analgesics	64	Mouth & dental analgesics	131
Topical analgesics	70	Outlook	134
Mouth & dental analgesics	75		
Outlook	77		

Table of Contents

Germany	136	Japan	188
Overview	136	Overview	188
Systemic analgesics	140	Systemic analgesics	192
Topical analgesics	146	Topical analgesics	197
Mouth & dental analgesics	151	Mouth & dental analgesics	202
Outlook	153	Outlook	203
India	155	Mexico	205
Overview	155	Overview	205
Systemic analgesics	159	Systemic analgesics	209
Topical analgesics	163	Topical analgesics	216
Outlook	168	Mouth & dental analgesics	220
Italy	170	Outlook	222
Overview	170	Poland	224
Systemic analgesics	174	Overview	224
Topical analgesics	179	Systemic analgesics	228
Mouth & dental analgesics	184	Topical analgesics	232
Outlook	186	Mouth & dental analgesics	236
		Outlook	238

Table of Contents

Russia	240	Brand Case Studies	301
Overview	240	Advil	301
Systemic analgesics	244	Nurofen	304
Topical analgesics	248	Panadol	307
Mouth & dental analgesics	253	Tylenol	310
Outlook	255	Voltaren	313
UK	257	Scientific Studies	316
Overview	257	Outlook & Prospects	324
Systemic analgesics	261	Global outlook	324
Topical analgesics	266	Asia-Pacific	327
Mouth & dental analgesics	271	North America	330
Outlook	274	Western Europe	332
USA	276	C&E Europe	335
Overview	276	Latin America	337
Systemic analgesics	280		
Topical analgesics	287		
Mouth & dental analgesics	297		
Outlook	299		